The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Your total testosterone number is a starting point, and most of the time it is treated like a finish line.

A doctor runs the test, sees a number somewhere between 300 and 1000 ng/dL, and tells you that you are within the normal range. That range, established from a harmonized study of 9,054 men, sits between 264 and 916 ng/dL. You are technically fine. But "fine" covers an enormous amount of ground, and a single number without context cannot tell you why you feel the way you feel or what is actually driving the pattern.

Here is the full picture of what that context looks like, and why each layer matters.

Start with the hormonal system itself, because that is where most single-lab interpretations fall apart.

The endocrine system runs on a chain of signals. Your brain sends a message through something called LH, which stands for luteinizing hormone and is essentially the electrical pulse your pituitary sends to tell your testes to produce testosterone. Your testes respond, testosterone rises, the brain senses it and backs off the signal. That feedback loop runs continuously. The problem is that a low testosterone number can mean two completely different things depending on where in that chain the breakdown is happening.

If your LH is elevated and your testosterone is still low, the problem is your testes not responding to the signal. That is primary hypogonadism. If your LH is low or normal alongside low testosterone, the problem is your brain not sending a strong enough signal in the first place. That is secondary hypogonadism. The Endocrine Society clinical guidelines specifically require distinguishing between these two before starting treatment, because the treatment path is different. Running testosterone without knowing which type you have is like replacing a car battery when the problem is actually the alternator.

Most standard panels skip LH entirely, which means the mechanism behind the low number stays unknown.

SHBG, which stands for sex hormone-binding globulin and is essentially a protein that binds testosterone in your bloodstream and renders it inactive, is the other piece that almost never gets tested in routine care. A man with 600 ng/dL of total testosterone but very high SHBG can have less biologically available testosterone than a man sitting at 400 ng/dL with low SHBG, because only the unbound portion can actually interact with receptors in your cells. Free testosterone measures that unbound fraction directly. Without SHBG and free testosterone alongside total testosterone, the total number is missing its own denominator.

Prolactin, DHEA-S, progesterone, and cortisol round out the hormonal picture. Elevated prolactin can suppress the entire HPG axis independently of testosterone, and it is something that gets missed on standard labs routinely. Cortisol matters because chronic stress physiology and hormone production share upstream resources, and high cortisol over time suppresses downstream hormone output.

The metabolic layer is where a lot of practitioners draw an artificial line between "hormone health" and "metabolic health," and that line does not actually exist in the body.

Insulin resistance is the condition worth paying attention to here, and the standard fasting glucose test often does not catch it early. You can have completely normal fasting blood sugar while your pancreas is working three to four times harder than it should be to hold that number steady. That is because the pancreas compensates for early insulin resistance by simply producing more insulin, so glucose stays normal while the underlying dysfunction builds. The test that catches this is fasting insulin alongside glucose, not glucose alone. Hemoglobin A1c gives you a 90-day average of blood sugar regulation and adds another data point that a single fasting draw cannot.

This matters for hormonal health directly, because insulin resistance is one of the mechanisms that suppresses SHBG and alters testosterone metabolism. You cannot fully understand the hormonal picture without the metabolic one.

Cardiovascular risk markers follow the same logic.

A standard lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. These are useful, but they describe cholesterol concentrations, not the actual driver of arterial plaque. Apolipoprotein B, or ApoB, measures the total count of atherogenic lipoprotein particles circulating in your blood. Two men can have identical LDL cholesterol numbers but very different ApoB counts depending on the size and density of their particles, and it is the particle count, not the cholesterol mass, that correlates more directly with cardiovascular events. High-sensitivity CRP, or hs-CRP, adds the inflammation dimension, because arterial damage requires both the particles and the inflammatory environment for plaque to develop and progress.

These are baseline markers before a protocol starts, not because TRT is inherently dangerous, but because testosterone drives erythropoiesis, which is the production of red blood cells, and hematocrit is the metric that reflects that process. Research published in the Journal of Urology found that men on testosterone therapy with a hematocrit at or above 52% faced a 35% higher risk of major adverse cardiovascular events and venous thromboembolism compared to those below that threshold. That is not a reason to avoid testosterone, it is a reason to know your baseline hematocrit and track it through a protocol.

The thyroid panel completes the picture that standard care typically leaves incomplete. TSH alone measures the brain's signal to the thyroid, but not how well the thyroid is actually executing on that signal. Free T3 is the active thyroid hormone at the cellular level. Free T4 is the storage form that converts to T3. A man can have a normal TSH while his conversion from T4 to T3 is impaired, which means his cells are running on inadequate thyroid hormone even though the signaling pathway looks intact. The symptoms of low free T3, fatigue, slow metabolism, poor recovery, overlap substantially with low testosterone symptoms, which means treating one without ruling out the other leads to partial solutions at best.

IGF-1 belongs on a pre-protocol panel for anyone considering growth hormone secretagogues or peptides. It is the downstream marker that reflects growth hormone output, and without a baseline measurement before starting a protocol, there is no way to objectively assess whether the intervention is producing a meaningful response. You are guessing without it.

The reason all of this matters goes beyond building a better checklist.

A single number, even when it is "in range," sits inside a web of systems that all talk to each other, and treating one variable without mapping the surrounding variables is how people end up on protocols that help some things and miss others entirely. The labs are not the protocol. The labs are what makes the protocol make sense.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness